Makale detayı · 2023
TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease
Dergi
Kare PublishingISSN 1307-5888
ISSN kaydı başka bir dergiye işaret ediyor; ad YÖKSİS kaydından.
- Yıl
- 2023
- Tür
- article
Veri kaynağı ayrımı
- YÖKSİS YÖKSİS makale kaydı
- YÖKSİS dergi adı Kare Publishing
- Katalog eşleşmesi (ISSN) Hepatology Forum
- OpenAlex OpenAlex zenginleştirmesi (özet, atıf, konular)
Özet
OpenAlex · İngilizce
Nonalcoholic fatty liver disease (NAFLD) is a multisystem disease and is significantly associated with obesity, insulin resistance, type 2 diabetes mellitus, metabolic syndrome, and cardiovascular disease. NAFLD has become the most prevalent chronic liver disease in Western countries, and the proportion of NAFLD-related cirrhosis among patients on liver transplantation waiting lists has increased. In light of the accumulated data about NAFLD, and to provide a common approach with multi-disciplines dealing with the subject, it has become necessary to create new guidance for diagnosing and treating NAFLD. This guidance was prepared following an interdisciplinary study under the leadership of the Turkish Association for the Study of the Liver (TASL), Fatty Liver Special Interest Group. This new TASL Guidance is a practical application guide on NAFLD and was prepared to standardize the clinical approach to diagnosing and treating NAFLD patients. This guidance reflects many advances in the field of NAFLD. The proposals in this guidance are meant to aid decision-making in clinical practice. The guidance is primarily intended for gastroenterology, endocrinology, metabolism diseases, cardiology, internal medicine, pediatric specialists, and family medicine specialists.
Konular
Atıflar
OpenAlex cited_by_count. WoS veya Scopus atıf sayısı değildir; o kaynaklar için ayrı kolon yoktur.
14 atıf
OpenAlex cited_by_count (önbellek / veritabanı)
Yerel katalogda bu makaleye atıf yapan 10 yayın (OpenAlex referans eşleşmesi; tam dünya listesi değildir).
- Investigating hepatic fibrosis heterogeneity by three-dimensional imaging in metabolic dysfunction-associated steatotic liver disease 2025
- Investigating hepatic fibrosis heterogeneity by three-dimensional imaging in metabolic dysfunction-associated steatotic liver disease 2025
- Prevalence, determinants, and fibrosis risk stratification of metabolic-associated fatty liver disease in a Turkish primary care setting: A retrospective study 2024
- Correlation between ultrasonography and MR proton density fat fraction techniques in evaluating the severity of liver steatosis 2024
- Correlation between ultrasonography and MR proton density fat fraction techniques in evaluating the severity of liver steatosis 2024
- Prevalence, determinants, and fibrosis risk stratification of metabolic-associated fatty liver disease in a Turkish primary care setting: a retrospective study 2023
- Histological disease progression in patients with metabolic dysfunction-associated steatotic liver disease using paired liver biopsy 2026
- Histological disease progression in patients with metabolic dysfunction–associated steatotic liver disease using paired liver biopsy 2025
- Ten‐Year Follow‐Up After 96 Weeks Treatment With Peginterferon Plus Tenofovir in Hepatitis D (HIDIT‐II): Improved Clinical Outcome After Combination Therapy 2025
- Histological disease progression in patients with metabolic dysfunction–associated steatotic liver disease using paired liver biopsy 2025